Human lab research clarifies cannabis use disorder mechanisms
Human behavioral pharmacology of Cannabis: Insights on Cannabis use disorder.
AI Summary
This narrative review asks how human behavioral-pharmacology research can model Cannabis use disorder (CUD) and guide the development of treatments. It synthesizes findings from over 25 years of human laboratory research, focusing on how dose, placebo control, and behavior-specific measurements help separate the pharmacological effects of Cannabis from expectancy and other influences.
The review highlights three main insights: people may change their inhalation patterns when cannabis strength changes, so product potency does not directly equal the Δ9-tetrahydrocannabinol (THC) dose received; placebo responses can be substantial even among experienced cannabis smokers; and medications may affect CUD-related behaviors such as reinforcement and misuse-related ratings, as well as non-specific effects such as sedation. These effects can differ according to participant characteristics. The abstract does not provide quantitative treatment outcomes, and because this is a narrative review—not a new clinical trial—it cannot establish that any medication is effective or that laboratory behaviors reliably predict clinical benefit. This is an abstract-based summary and does not assess the full text.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More THC research papers you might find interesting.
Review links acute, high-THC cannabis use with cardiovascular risks
A planned pilot trial will test cannabis gummy feasibility for cancer-related…
Mouse study finds stronger effects for THCP than for delta-8 THC or CBN
Explore More Research
Stay informed about the latest cannabis science.